
Arend F L Schinkel

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5470099/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Relation Between Early Diastolic Mid-Ventricular Flow and Elastic Forces Indicating Aneurysm Formation in Hypertrophic Cardiomyopathy. Journal of the American Society of Echocardiography, 2022, , .	1.2	5
2	Contemporary family screening in hypertrophic cardiomyopathy: the role of cardiovascular magnetic resonance. European Heart Journal Cardiovascular Imaging, 2022, 23, 1144-1154.	0.5	4
3	Evaluation of patients with a HeartMate 3 left ventricular assist device using echocardiographic particle image velocimetry. Journal of Ultrasound, 2021, 24, 499-503.	0.7	3
4	Left-ventricular outflow tract acceleration time is associated with symptoms in patients with obstructive hypertrophic cardiomyopathy. Journal of Ultrasound, 2021, 24, 279-287.	0.7	1
5	Impact of sex on timing and clinical outcome of septal myectomy for obstructive hypertrophic cardiomyopathy. International Journal of Cardiology, 2021, 323, 133-139.	0.8	8
6	Patent foramen ovale and wake-up stroke. European Heart Journal - Case Reports, 2021, 5, ytaa576.	0.3	0
7	Novel Morphological Features on CMR for the Prediction of Pathogenic Sarcomere Gene Variants in Subjects Without Hypertrophic Cardiomyopathy. Frontiers in Cardiovascular Medicine, 2021, 8, 727405.	1.1	4
8	Contrast-Enhanced Ultrasound to Assess Carotid Intraplaque Neovascularization. Ultrasound in Medicine and Biology, 2020, 46, 466-478.	0.7	36
9	Hunting the Vulnerable Carotid Plaque: In Search of a Gold Standard. Ultrasound in Medicine and Biology, 2020, 46, 3169.	0.7	Ο
10	Frequency and Significance of Coronary Artery Disease and Myocardial Bridging in Patients With Hypertrophic Cardiomyopathy. American Journal of Cardiology, 2020, 125, 1404-1412.	0.7	19
11	Protein Quality Control Activation and Microtubule Remodeling in Hypertrophic Cardiomyopathy. Cells, 2019, 8, 741.	1.8	26
12	Meta-Analysis of Clinical Outcome After Implantable Cardioverter-Defibrillator Implantation in Patients With BrugadaÂSyndrome. JACC: Clinical Electrophysiology, 2019, 5, 141-148.	1.3	22
13	Functional imaging in echocardiography can sometimes replace direct structure visualization. European Heart Journal Cardiovascular Imaging, 2019, 20, 241-241.	0.5	1
14	Prediction of long-term (> 10 year) cardiovascular outcomes in heart transplant recipients: Value of stress technetium-99m tetrofosmin myocardial perfusion imaging. Journal of Nuclear Cardiology, 2019, 26, 845-852.	1.4	11
15	Outcomes of Contemporary Family Screening in Hypertrophic Cardiomyopathy. Circulation Genomic and Precision Medicine, 2018, 11, e001896.	1.6	52
16	Value of implantable loop recorders in patients with structural or electrical heart disease. Journal of Interventional Cardiac Electrophysiology, 2018, 52, 203-208.	0.6	15
17	Three-dimensional echocardiography for the assessment of left ventricular geometry and papillary muscle morphology in hypertrophic cardiomyopathy. Journal of Ultrasound, 2018, 21, 17-24.	0.7	8
18	Cardiac stress imaging for the prediction of very long-term outcomes: Dobutamine stress echocardiography or dobutamine 99mTc-sestamibi SPECT?. Journal of Nuclear Cardiology, 2018, 25, 471-479.	1.4	1

#	Article	IF	CITATIONS
19	Prediction of 14-year cardiovascular outcomes by dobutamine stress 99mTc-tetrofosmin myocardial perfusion SPECT in elderly patients unable to perform exercise testing. Journal of Nuclear Cardiology, 2018, 25, 63-71.	1.4	6
20	Ischemia burden on stress SPECT MPI predicts long-term outcomes after revascularization in stable coronary artery disease. Journal of Nuclear Cardiology, 2018, 25, 958-966.	1.4	10
21	Safety and feasibility of contrast echocardiography for the evaluation of patients with HeartMate 3 left ventricular assist devices. European Heart Journal Cardiovascular Imaging, 2018, 19, 690-693.	0.5	11
22	Effect of Gender and Genetic Mutations on Outcomes in Patients With Hypertrophic Cardiomyopathy. American Journal of Cardiology, 2018, 122, 1947-1954.	0.7	27
23	Prognostic significance of anterior mitral valve leaflet length in individuals with a hypertrophic cardiomyopathy gene mutation without hypertrophic changes. Journal of Ultrasound, 2018, 21, 217-224.	0.7	5
24	Effect of alcohol dosage on longâ€ŧerm outcomes after alcohol septal ablation in patients with hypertrophic cardiomyopathy. Catheterization and Cardiovascular Interventions, 2016, 88, 945-952.	0.7	5
25	Delayed and decreased LV untwist and unstrain rate in mutation carriers for hypertrophic cardiomyopathy. European Heart Journal Cardiovascular Imaging, 2016, 18, jew213.	0.5	10
26	Value of Genetic Testing for the Prediction of Long-Term Outcome in Patients With Hypertrophic Cardiomyopathy. American Journal of Cardiology, 2016, 118, 881-887.	0.7	32
27	Impact of Early Coronary Revascularization on Long-Term Outcomes in Patients With Myocardial Ischemia on Dobutamine Stress Echocardiography. American Journal of Cardiology, 2016, 118, 635-640.	0.7	5
28	Long-Term (>10 Years) Prognostic Value of Dobutamine Stress Echocardiography in a High-Risk Cohort. American Journal of Cardiology, 2016, 117, 1078-1083.	0.7	8
29	Contrast-enhanced ultrasound: clinical applications in patients with atherosclerosis. International Journal of Cardiovascular Imaging, 2016, 32, 35-48.	0.7	70
30	Prediction of 14-year outcomes in patients with a limited exercise capacity: Utility of dobutamine myocardial perfusion imaging in a high-risk population. Journal of Nuclear Cardiology, 2015, 22, 888-900.	1.4	1
31	Validation of the 2014 European Society of Cardiology Guidelines Risk Prediction Model for the Primary Prevention of Sudden Cardiac Death in Hypertrophic Cardiomyopathy. Circulation: Arrhythmia and Electrophysiology, 2015, 8, 829-835.	2.1	113
32	Eleven-Year Prognostic Value of Dobutamine Stress 99mTc-Sestamibi Myocardial Perfusion Imaging in Patients With Limited Exercise Capacity. American Journal of Cardiology, 2015, 115, 884-889.	0.7	11
33	Eight-Year Prognostic Value of QRS Duration in Patients With Known or Suspected Coronary Artery Disease Referred for Myocardial Perfusion Imaging. American Journal of Cardiology, 2015, 116, 1329-1333.	0.7	3
34	Identifying genetic risk variants for coronary heart disease in familial hypercholesterolemia: an extreme genetics approach. European Journal of Human Genetics, 2015, 23, 381-387.	1.4	15
35	Impact of Adverse Left Ventricular Remodeling on Sudden Cardiac Death in Patients With Hypertrophic Cardiomyopathy. Clinical Cardiology, 2014, 37, 493-498.	0.7	12
36	New Quantification Methods for Carotid Intra-plaque Neovascularization Using Contrast-Enhanced Ultrasound. Ultrasound in Medicine and Biology, 2014, 40, 25-36.	0.7	45

#	Article	IF	CITATIONS
37	Impact of gender on the density of intraplaque neovascularization: AÂquantitative contrast-enhanced ultrasound study. Atherosclerosis, 2014, 233, 461-466.	0.4	9
38	Assessment of carotid atherosclerosis, intraplaque neovascularization, and plaque ulceration using quantitative contrast-enhanced ultrasound in asymptomatic patients with diabetes mellitus. European Heart Journal Cardiovascular Imaging, 2014, 15, 1213-1218.	0.5	36
39	Joint intensity-and-point based registration of free-hand B-mode ultrasound and MRI of the carotid artery. Medical Physics, 2014, 41, 052904.	1.6	7
40	Molecular Imaging of Inflammation and Intraplaque Vasa Vasorum. , 2014, , 299-316.		0
41	12-Year outcome after normal myocardial perfusion SPECT in patients with known coronary artery disease. Journal of Nuclear Cardiology, 2013, 20, 748-754.	1.4	24
42	What is the value of stress 99mTc-tetrofosmin myocardial perfusion imaging for the assessment of very long-term outcome in obese patients?. Journal of Nuclear Cardiology, 2013, 20, 227-233.	1.4	15
43	Implantable Cardioverter Defibrillators in Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy. Circulation: Arrhythmia and Electrophysiology, 2013, 6, 562-568.	2.1	101
44	Current status and future developments of contrast-enhanced ultrasound of carotid atherosclerosis. Journal of Vascular Surgery, 2013, 57, 539-546.	0.6	80
45	Prediction of 8-year cardiovascular outcomes in patients with systemic arterial hypertension: Value of stress 99mTc-tetrofosmin myocardial perfusion imaging in a high-risk cohort. Journal of Nuclear Cardiology, 2013, 20, 1030-1040.	1.4	3
46	Implantable cardioverter-defibrillators in hypertrophic cardiomyopathy: Patient outcomes, rate of appropriate and inappropriate interventions, and complications. American Heart Journal, 2013, 166, 496-502.	1.2	82
47	Carotid intima-media thickness for cardiovascular risk assessment: Systematic review and meta-analysis. Atherosclerosis, 2013, 228, 1-11.	0.4	239
48	Assessment of subclinical atherosclerosis and intraplaque neovascularization using quantitative contrast-enhanced ultrasound in patients with familial hypercholesterolemia. Atherosclerosis, 2013, 231, 107-113.	0.4	31
49	Far wall pseudo-enhancement: A neglected artifact in carotid contrast-enhanced ultrasound?. Atherosclerosis, 2013, 229, 451-452.	0.4	8
50	Usefulness of Contrast-Enhanced Ultrasound for Detection of Carotid Plaque Ulceration in Patients With Symptomatic CarotidÂAtherosclerosis. American Journal of Cardiology, 2013, 112, 292-298.	0.7	75
51	Effect of Carotid Plaque Screening Using Contrast-Enhanced Ultrasound on Cardiovascular Risk Stratification. American Journal of Cardiology, 2013, 111, 754-759.	0.7	23
52	Assessment of subclinical atherosclerosis using contrast-enhanced ultrasound. European Heart Journal Cardiovascular Imaging, 2013, 14, 56-61.	0.5	17
53	Statistical segmentation of carotid plaque neovascularization. Proceedings of SPIE, 2013, , .	0.8	4
54	Regional left ventricular rotation and back-rotation in patients with reverse septal curvature hypertrophic cardiomyopathy. European Heart Journal Cardiovascular Imaging, 2013, 14, 435-442.	0.5	6

#	Article	IF	CITATIONS
55	New quantification methods for carotid intraplaque neovascularization in contrast enhanced ultrasound. , 2013, , .		0
56	Long-Term Prognostic Value of Dobutamine Stress Echocardiography in Diabetic Patients With Limited Exercise Capability: A 13-year follow-up study. Diabetes Care, 2012, 35, 634-639.	4.3	16
57	Prediction of 9-year cardiovascular outcomes by myocardial perfusion imaging in patients with normal exercise electrocardiographic testing. European Heart Journal Cardiovascular Imaging, 2012, 13, 900-904.	0.5	6
58	Far-Wall Pseudoenhancement During Contrast-Enhanced Ultrasound of the Carotid Arteries: Clinical Description andÂInÂVitro Reproduction. Ultrasound in Medicine and Biology, 2012, 38, 593-600.	0.7	66
59	Long-term prognostic value of exercise technetium-99m tetrofosmin myocardial perfusion single-photon emission computed tomography. Journal of Nuclear Cardiology, 2012, 19, 907-913.	1.4	21
60	15-Year outcome after normal exercise 99mTc-sestamibi myocardial perfusion imaging: What is the duration of low risk after a normal scan?. Journal of Nuclear Cardiology, 2012, 19, 901-906.	1.4	21
61	Outcome and Complications After Implantable Cardioverter Defibrillator Therapy in Hypertrophic Cardiomyopathy. Circulation: Heart Failure, 2012, 5, 552-559.	1.6	150
62	More on advances in imaging angiogenesis and inflammation in atherosclerosis. Thrombosis and Haemostasis, 2011, 105, 920-921.	1.8	0
63	Correlation of Carotid Artery Atherosclerotic Lesion Echogenicity and Severity at Standard US with Intraplaque Neovascularization Detected at Contrast-enhanced US. Radiology, 2011, 258, 618-626.	3.6	128
64	Contrast enhanced ultrasound imaging. Journal of Nuclear Cardiology, 2010, 17, 106-115.	1.4	77
65	Molecular imaging of inflammation and intraplaque vasa vasorum: A step forward to identification of vulnerable plaques?. Journal of Nuclear Cardiology, 2010, 17, 897-912.	1.4	55
66	Noninvasive Imaging of the Vulnerable Atherosclerotic Plaque. Current Problems in Cardiology, 2010, 35, 556-591.	1.1	64
67	Contrast-enhanced ultrasound for imaging vasa vasorum: comparison with histopathology in a swine model of atherosclerosis. European Journal of Echocardiography, 2010, 11, 659-664.	2.3	56
68	Contrast-Enhanced Ultrasound Imaging of the Vasa Vasorum. JACC: Cardiovascular Imaging, 2010, 3, 761-771.	2.3	156
69	Incidence, Pathophysiology, and Treatment of Complications During Dobutamine-Atropine Stress Echocardiography. Circulation, 2010, 121, 1756-1767.	1.6	96
70	Pre-Procedural Dual Source 64-Slice Computed Tomography in Unprotected Left Main Intervention. JACC: Cardiovascular Interventions, 2009, 2, 470-471.	1.1	2
71	Prognostic Significance of QRS Duration in Patients With Suspected Coronary Artery Disease Referred for Noninvasive Evaluation of Myocardial Ischemia. American Journal of Cardiology, 2009, 104, 1490-1493.	0.7	22
72	Assessment of Myocardial Viability in Patients with Heart Failure. Journal of Nuclear Medicine, 2007, 48, 1135-1146.	2.8	126

#	Article	IF	CITATIONS
73	Prognostic Implications of a Normal Stress Technetium-99m–Tetrofosmin Myocardial Perfusion Study in Patients With a Healed Myocardial Infarct and/or Previous Coronary Revascularization. American Journal of Cardiology, 2006, 97, 1-6.	0.7	23
74	Stress and tissue Doppler echocardiographic evidence of effectiveness of myoblast transplantation in patients with ischaemic heart failure. European Journal of Heart Failure, 2006, 8, 641-648.	2.9	28
75	Benefits of coronary revascularisation in diabetic and non-diabetic patients with ischaemic cardiomyopathy: Role of myocardial viability. European Journal of Heart Failure, 2006, 8, 314-320.	2.9	5
76	Letter by Schinkel et al Regarding Article, "Projected Valve Area at Normal Flow Rate Improves the Assessment of Stenosis Severity in Patients With Low-Flow, Low-Gradient Aortic Stenosis: The Multicenter TOPAS (Truly or Pseudo-Severe Aortic Stenosis) Study― Circulation, 2006, 114, e526; author reply e527.	1.6	0
77	Impact of diabetes mellitus on prediction of clinical outcome after coronary revascularization by 18F-FDG SPECT in patients with ischemic left ventricular dysfunction. Journal of Nuclear Medicine, 2006, 47, 68-73.	2.8	5
78	Prognostic stratification of obese patients by stress 99mTc-tetrofosmin myocardial perfusion imaging. Journal of Nuclear Medicine, 2006, 47, 1302-6.	2.8	15
79	Comparison of All-Cause Mortality in Women With Known or Suspected Coronary Artery Disease Referred for Dobutamine Stress Echocardiography With Normal Versus Abnormal Test Results. American Journal of Cardiology, 2005, 95, 1072-1075.	0.7	7
80	Incremental prognostic value of dobutamine–atropine stress 99mTc-tetrofosmin myocardial perfusion imaging for predicting outcome in diabetic patients with limited exercise capacity. European Journal of Nuclear Medicine and Molecular Imaging, 2005, 32, 1057-1063.	3.3	8
81	Long-Term Prediction of Mortality in Elderly Persons by Dobutamine Stress Echocardiography. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2005, 60, 1333-1338.	1.7	27
82	Clinical assessment of myocardial hibernation. Heart, 2005, 91, 111-117.	1.2	27
83	Prognostic stratification using dobutamine stress 99mTc-tetrofosmin myocardial perfusion SPECT in elderly patients unable to perform exercise testing. Journal of Nuclear Medicine, 2005, 46, 12-8.	2.8	140
84	QT dispersion correlates to myocardial viability assessed by dobutamine stress echocardiography in patients with severely depressed left ventricular function due to coronary artery disease. European Journal of Heart Failure, 2004, 6, 187-193.	2.9	6
85	Incremental value of exercise technetium-99m tetrofosmin myocardial perfusion single-photon emission computed tomography for the prediction of cardiac events. American Journal of Cardiology, 2003, 91, 408-411.	0.7	42
86	Long-term prognosis after a normal exercise stress Tc-99m sestamibi SPECT study. Journal of Nuclear Cardiology, 2003, 10, 261-266.	1.4	67
87	Statins Are Associated With a Reduced Incidence of Perioperative Mortality in Patients Undergoing Major Noncardiac Vascular Surgery. Circulation, 2003, 107, 1848-1851.	1.6	465
88	Prognostic Value of Dobutamine Stress Echocardiography in Patients With Diabetes. Diabetes Care, 2003, 26, 1074-1078.	4.3	64
89	Screening for left ventricular dysfunction using a hand-carried cardiac ultrasound device. European Journal of Heart Failure, 2003, 5, 767-774.	2.9	56
90	Prediction of cardiac death in hypertensive patients with suspected or known coronary artery disease by stress technetium-99m tetrofosmin myocardial perfusion imaging. Journal of Hypertension, 2003, 21, 1945-1951.	0.3	16

#	Article	IF	CITATIONS
91	Dobutamine-induced contractile reserve in stunned, hibernating, and scarred myocardium in patients with ischemic cardiomyopathy. Journal of Nuclear Medicine, 2003, 44, 127-33.	2.8	20
92	Effect of diabetes mellitus on myocardial 18F-FDG SPECT using acipimox for the assessment of myocardial viability. Journal of Nuclear Medicine, 2003, 44, 877-83.	2.8	27
93	Long-term Prognostic Value of Dobutamine Stress99mTc-Sestamibi SPECT: Single-Center Experience with 8-year Follow-up. Radiology, 2002, 225, 701-706.	3.6	26
94	Prognostic Value of Dobutamine-Atropine Stress Myocardial Perfusion Imaging in Patients With Diabetes. Diabetes Care, 2002, 25, 1637-1643.	4.3	27
95	Prognostic value of dobutamine-atropine stress (99m)Tc-tetrofosmin myocardial perfusion SPECT in patients with known or suspected coronary artery disease. Journal of Nuclear Medicine, 2002, 43, 767-72.	2.8	27